secwatch.observer — SEC 8-K summary
======================================

Issuer:     SQZ Biotechnologies Co (—)
CIK:        0001604477
Form:       8-K
Filed at:   2023-06-15T23:59:59+00:00
Accession:  0000950170-23-028324
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01, 5.07, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

SQZ Biotech receives NYSE delisting notice; approves 1-for-10 reverse split
---------------------------------------------------------------------------

- NYSE notified SQZ that avg market cap and stockholders' equity each <$50M; company plans to submit cure plan within 45 days.
- Shareholders approved reverse stock split at ratio of 1:10 (Board discretion) with 23,057,854 votes for, 476,649 against.
- Board set reverse split at 1-for-10, effective July 6, 2023 at 5:00 PM ET; split-adjusted trading begins July 7 under SQZ.
- No immediate impact on listing; if plan not accepted, NYSE could initiate delisting proceedings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604477/000095017023028324/0000950170-23-028324-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604477/000095017023028324/sqz-20230612.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-028324

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer